NJ Victories For Novartis To Curb Zometa Pile-On Suits

Law360, New York (June 14, 2013, 8:29 PM EDT) -- A New Jersey appellate decision Friday refusing to revive a mass tort lawsuit against Novartis Pharmaceuticals Corp. over its bone medication Zometa should give businesses even more certainty on statute of limitations questions and adds to a string of victories for the drugmaker in the state that could discourage weaker cases, experts said.

Novartis has shouldered hefty plaintiff verdicts in other state and federal litigation alleging it had obscured dead jaw bone risks associated with the bisphosphonate drug Zometa and its less potent predecessor Aredia. But...
To view the full article, register now.